Sudden cardiac death in heart failure trial l.jpg
This presentation is the property of its rightful owner.
Sponsored Links
1 / 4

Sudden Cardiac Death in Heart Failure Trial PowerPoint PPT Presentation


  • 94 Views
  • Uploaded on
  • Presentation posted in: General

SCD-HeFT. Sudden Cardiac Death in Heart Failure Trial. Presented at American College of Cardiology Scientific Sessions 2004 Presented by Dr. Gust H. Bardy. SCD-HeFT. 2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ≤35% Randomized, double-blind, multicenter.

Download Presentation

Sudden Cardiac Death in Heart Failure Trial

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Sudden cardiac death in heart failure trial l.jpg

SCD-HeFT

Sudden Cardiac Death in Heart Failure Trial

Presented at

American College of Cardiology

Scientific Sessions 2004

Presented by Dr. Gust H. Bardy


Scd heft l.jpg

SCD-HeFT

2,521 patients with moderately symptomatic CHF (NYHA Class II or III) and LVEF ≤35%

Randomized, double-blind, multicenter

Conventional CHF Treatment + Placebo

Conventional CHF Treatment + ICD

Single lead implantable cardioverter defibrillator programmed for ventricular fibrillation (VF) treatment only

  • Conventional CHF Treatment + Amiodarone

  • Antiarrhythmic agent

    • 800 mg Week 1, 400 mg Week 2-4

    • Chronic therapy:

      • 200 mg/day if <150 lbs

      • 300 mg/day if 150-200 lbs

      • 400 mg/day if >200 lbs

Treatment

  • Endpoints (median 45.5 months):

    All-cause mortality

Presented at ACC Scientific Sessions 2004


Slide3 l.jpg

SCD-HeFT

All-cause mortality at 5 years

Amiodarone vs placebo

HR 1.06, p=0.529

ICD vs placebo

HR 0.77, p=0.007

  • Medication use at end of follow-up included 72% ACE-inhibitors, 78% beta-blockers, 80% loop diuretics, and 55% ASA

  • Prior duration of CHF was 24.5 months at baseline

  • No difference in all-cause mortality between amiodarone and placebo arm

  • Mortality was lower in ICD arm vs placebo

% Mortality

Presented at ACC Scientific Sessions 2004


Slide4 l.jpg

SCD-HeFT

  • Among patients with NYHA Class II or Class III CHF and reduced left ventricular ejection fraction, treatment with an implantable ICD was associated with a reduction in all-cause mortality compared with placebo, but there was no difference between amiodarone and placebo

  • Secondary endpoint data not yet reported


  • Login